Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Vertiv Holdings Co (VRT) vs Zoetis Inc (ZTS) Price & Performance

Vertiv Holdings CoTrade
Zoetis IncTrade

Price performance (Past 24H)

Key statistics

Vertiv Holdings Co vs Zoetis Inc — how do they compare? Vertiv Holdings Co trades at $285.77 (market cap $103.99B), while Zoetis Inc trades at $75.23 (market cap $30.92B). The key difference: Vertiv Holdings Co is far larger — about 3.4× Zoetis Inc's market cap, and Zoetis Inc pays the higher dividend (2.83%). Which is the better fit depends on your goals.

VRTZTS
Market Cap
$103.99B$30.92B
Sector
TechnologyHealth
52-Week High
$376.23$156.76
52-Week Low
$121.82$71.91
Enterprise Value
$104.21B$38.49B
Dividend Yield
0.09%2.83%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Vertiv Holdings Co

VRT trades at $272.40, down 1.01% on the day, with a bearish technical signal driven by moving averages and RSI levels near overbought territory. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.52 versus $1.43 expected, and revenue growth is supported by AI data center demand. Recent news highlights its role in AI infrastructure, though legal investigations pose a sentiment risk.

Outlook remains positive with a consensus price target of $386.58, reflecting 42% upside, driven by robust fundamentals and AI tailwinds. Risks include high valuation multiples, competitive pressures, and ongoing legal scrutiny. Investors should weigh growth potential against elevated P/E and market volatility.

Zoetis Inc

Zoetis (ZTS) trades at $72.66, down 5.92% amid a bearish technical signal and recent earnings pressure. The stock is near its 52-week low after Piper Sandler cut its price target to $80.00 on August 11, 2026. Despite strong profitability with a net margin of 27.69% and ROE of 64.91%, Q2 2026 revenue missed estimates, and the company reduced its 2026 outlook due to softer pet healthcare demand. Cash flow improved in 2025 with net cash flow of $325 million, but debt-to-asset ratio remains elevated at 46.14%.

The outlook is cautious with near-term headwinds in companion animal markets, but long-term fundamentals remain solid given the company's leading position in animal health. Risks include competitive pressures and a class action lawsuit. Analyst consensus is a Buy with a $95.00 price target, implying significant upside if execution improves.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Vertiv Holdings Co

Vertiv is a global leader in critical digital infrastructure, providing essential power, cooling, and IT management solutions for data centers, communication networks, and industrial facilities. As the primary provider of advanced thermal management and liquid cooling systems, Vertiv is a central player in the AI revolution, enabling the extreme density and power requirements of next-generation GPU-driven computing.

Read more on VRT

About Zoetis Inc

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Read more on ZTS